A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis.
暂无分享,去创建一个
[1] C. Weijer,et al. Reporting the study populations of clinical trials. Clear transmission or static on the line? , 2000, Journal of clinical epidemiology.
[2] C. González,et al. Determinants for the development of oropharyngeal colonization or infection by fluconazole-resistant Candida strains in HIV-infected patients. , 2000 .
[3] S J Pocock,et al. Randomized trials or observational tribulations? , 2000, The New England journal of medicine.
[4] S. Piscitelli,et al. Correlation between In Vitro and In Vivo Antifungal Activities in Experimental Fluconazole-Resistant Oropharyngeal and Esophageal Candidiasis , 2000, Journal of Clinical Microbiology.
[5] M. Lindegren,et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[6] J. Sobel,et al. Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[7] F. Mühlschlegel,et al. The Role of Candida dubliniensis in Oral Candidiasis in Human Immunodeficiency Virus-Infected Individuals , 2000, Critical reviews in microbiology.
[8] Daniel S. Miller,et al. Trends in self-reported use of mammograms (1989-1997) and Papanicolaou tests (1991-1997)--Behavioral Risk Factor Surveillance System. , 1999, MMWR. CDC surveillance summaries : Morbidity and mortality weekly report. CDC surveillance summaries.
[9] V. Andriole,et al. The 1998 Garrod lecture. Current and future antifungal therapy: new targets for antifungal agents. , 1999, The Journal of antimicrobial chemotherapy.
[10] M. Rinaldi,et al. In Vitro Activity of the New Echinocandin Antifungal, MK-0991, against Common and Uncommon Clinical Isolates of Candida Species , 1999, European Journal of Clinical Microbiology and Infectious Diseases.
[11] D. Soll,et al. In Vitro Susceptibilities of Candida dubliniensisIsolates Tested against the New Triazole and Echinocandin Antifungal Agents , 1999, Journal of Clinical Microbiology.
[12] Robin Patel,et al. Antifungal agents. Part I. Amphotericin B preparations and flucytosine. , 1998, Mayo Clinic proceedings.
[13] E. Anaissie,et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[14] S. Redding,et al. Clinical evaluation and microbiology of oropharyngeal infection due to fluconazole-resistant Candida in human immunodeficiency virus-infected patients. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[15] G. Noskin,et al. Amphotericin B colloidal dispersion for treatment of candidemia in immunocompromised patients. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[16] E. Anaissie,et al. Optimizing the Correlation between Results of Testing In Vitro and Therapeutic Outcome In Vivo for Fluconazole by Testing Critical Isolates in a Murine Model of Invasive Candidiasis , 1998, Antimicrobial Agents and Chemotherapy.
[17] J. Rex,et al. Point prevalence of oropharyngeal carriage of fluconazole-resistant Candida in human immunodeficiency virus-infected patients. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[18] J. Galgiani,et al. Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans , 1997, Antimicrobial agents and chemotherapy.
[19] J. Graybill,et al. Treatment of murine Candida krusei or Candida glabrata infection with L-743,872 , 1997, Antimicrobial agents and chemotherapy.
[20] J. Sobel,et al. In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species , 1997, Antimicrobial agents and chemotherapy.
[21] M. Henman,et al. Antifungal drug susceptibilities of oral Candida dubliniensis isolates from human immunodeficiency virus (HIV)-infected and non-HIV-infected subjects and generation of stable fluconazole-resistant derivatives in vitro , 1997, Antimicrobial agents and chemotherapy.
[22] J. Martínez-Suárez,et al. Patterns of fluconazole susceptibility in isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis due to Candida albicans. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[23] M. Ghannoum,et al. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Labora , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[24] S. Redding,et al. Detection and significance of fluconazole resistance in oropharyngeal candidiasis in human immunodeficiency virus-infected patients. , 1996, The Journal of infectious diseases.
[25] J. Martínez-Suárez,et al. In vitro activities of semisynthetic pneumocandin L-733,560 against fluconazole-resistant and -susceptible Candida albicans isolates , 1996, Antimicrobial agents and chemotherapy.
[26] T J Walsh,et al. Antifungal agents: chemotherapeutic targets and immunologic strategies , 1996, Antimicrobial agents and chemotherapy.
[27] J. Martínez-Suárez,et al. Patterns of in vitro activity of itraconazole and imidazole antifungal agents against Candida albicans with decreased susceptibility to fluconazole from Spain , 1995, Antimicrobial agents and chemotherapy.
[28] T. Flanigan,et al. Clinically significant mucosal candidiasis resistant to fluconazole treatment in patients with AIDS. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[29] C. Kauffman,et al. Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of fluconazole resistance. , 1994, The American journal of medicine.
[30] M. Trautmann,et al. Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection , 1994, Journal of clinical microbiology.
[31] C. Viscoli,et al. Developing improved observational methods for evaluating therapeutic effectiveness. , 1990, The American journal of medicine.
[32] M. Masiá Canuto,et al. Determinants for the Development of Oropharyngeal Colonization or Infection by Fluconazole-Resistant Candida Strains in HIV-Infected Patients , 2000, European Journal of Clinical Microbiology and Infectious Diseases.
[33] A. Oliver,et al. Outbreak of a multiresistant Klebsiella pneumoniae strain in an intensive care unit: antibiotic use as risk factor for colonization and infection. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[34] Guidelines for national human immunodeficiency virus case surveillance, including monitoring for human immunodeficiency virus infection and acquired immunodeficiency syndrome. Centers for Disease Control and Prevention. , 1999, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.
[35] M. Rinaldi,et al. In Vitro Activity of the New Echinocandin Antifungal, MK-0991, against Common and Uncommon Clinical Isolates of , 1999 .
[36] D. Landman,et al. Failure of all antifungal therapy for infection due to Candida albicans: a new AIDS-related problem? , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.